Latest Articles about BIOD

Pivotal Progresses with Vascazen - Analyst Blog

Zacks Equity Research — Wed, 17 Apr 2013 03:06:56 Z

Pivotal Therapeutics Inc. ( PVTTF ) recently announced encouraging top line data from the REVEAL study (n=110) on its cardiovascular candidate Vascazen in the US. Vascazen was successful in

Data on ArQule's ARQ 092 - Analyst Blog

Zacks Equity Research — Thu, 11 Apr 2013 01:10:01 Z

Researchers recently presented data on ArQule's ( ARQL ) ARQ 092 at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. The data revealed that the

Pre-Clinical Data on Ariad's Iclusig - Analyst Blog

Zacks Equity Research — Wed, 10 Apr 2013 02:09:59 Z

Ariad Pharmaceuticals, Inc. ( ARIA ) recently presented pre-clinical data on Iclusig (ponatinib). The company presented data which showed that Iclusig has the potential to inhibit RET and

Strategy is tailored for Biodel results

David Russell — Mon, 08 Apr 2013 11:06:01 Z

Biodel has major clinical data due later this year, and one investor tailored a strategy in hopes of good news. optionMONSTER's tracking systems detected the purchase of 4,000 September 4

ArQule Regains ARQ 092 Rights - Analyst Blog

Zacks Equity Research — Wed, 03 Apr 2013 02:20:01 Z

ArQule, Inc. ( ARQL ) recently announced that the company has regained global rights for the development and commercialization of compounds, which are covered under its AKT collaboration

Pipeline Progress at Biodel - Analyst Blog

Zacks Equity Research — Tue, 02 Apr 2013 01:08:32 Z

Biodel Inc. ( BIOD ) recently announced that it has completed enrolling patients in a phase II study on its diabetes candidate BIOD-123. In the study, BIOD-123 will be compared with Eli

Zacks #1 Rank Additions for Tuesday - Tale of the Tape

Zacks Equity Research — Tue, 14 Aug 2012 17:14:01 Z

Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Alliant Techsystems Inc. ( ATK ) Apogee Enterprises, Inc. ( APOG ) Arctic Cat Inc. ( ACAT )

Zacks #1 Rank Additions for Monday - Tale of the Tape

Zacks Equity Research — Mon, 16 Jul 2012 16:47:19 Z

Here are 5 stocks added to the Zacks #1 Rank ("strong buy") List today: Access National Corp. ( ANCX ) Alexza Pharmaceuticals, Inc. ( ALXA ) American Midstream Partners LP

4 Small Stocks with Buyout Rumors

David Sterman — Fri, 25 Mar 2011 21:00:00 Z

With a risingeconomy comes rising expectations. CEOs at mid-sized and large companies need to find new paths to growth to justify -- or boost -- their company's stock price. That's no mean feat

5 Top Stocks Under $5

David Sterman — Mon, 21 Feb 2011 22:00:00 Z

I'm a big fan of low-priced stocks -- especially those that are under $5 a share. At that level, mostmutual fund managers are restricted from owning them. But if growth plans pan out andshares

Option Activity Alert: Acme Packet, Inc. and Biodel Inc.

Schaeffer's Investment Research — Thu, 28 Oct 2010 19:25:33 Z

Traders rushed to place their bets on Acme Packet, Inc. ( APKT ) and Biodel Inc. ( BIOD ) on Wednesday, with option volume rising well beyond the norm for both stocks. Speculators are

Biodel draws two bearish positions

David Russell — Fri, 08 Oct 2010 10:05:22 Z

Biodel is pulling back after a big move, and traders are positioning for further downside. optionMONSTER's Depth Charge tracking system detected two separate bearish trades on the drug

How volatility seller is playing Biodel

David Russell — Fri, 24 Sep 2010 09:09:08 Z

Biodel has been rising on optimism about its Linjeta insulin product, and now one trader is selling volatility. optionMONSTER's tracking program detected the sale of 5,000 March 2.50 puts

Five Beaten-Down Stocks with +100% Upside Potential

David Sterman — Tue, 03 Aug 2010 23:59:48 Z

The coming months could prove to be an enticing time for investors. Many stocks are trading well off their highs under the assumption that the coming streams of economic data will prove to be

Friday Winners: Crocs Re-Emerges From the Dead

David Sterman — Fri, 07 May 2010 22:16:35 Z

Shares of Crocs (Nasdaq: CROX) continued their remarkable rebound, only a year after many had assumed that the once-hot footwear maker would not survive much longer. An impressive quarterly